36 Financial position and resources Financial position Property, plant and equipment GSKs business is science-based, technology-intensive and highly 2009 2008 m m regulated by governmental authorities.
The Group allocates significant financial resources to the renewal and maintenance of its Assets property, plant and equipment to minimise risks of interruption of Non-current assets production and to achieve compliance with regulatory standards.
Property, plant and equipment 9,374 9,678 A number of its processes use chemicals and hazardous materials.
Goodwill 3,361 2,101 Other intangible assets 8,183 5,869 The total cost of the Groups property, plant and equipment at Investments in associates and joint ventures 895 552 31st December 2009 was 18,757 million, with a net book value Other investments 454 478 of 9,374 million.
Of this, land and buildings represented Deferred tax assets 2,374 2,760 3,762 million, plant and equipment 3,433 million and assets Derivative financial instruments 68 107 in construction 2,179 million.
In 2009, GSK invested 583 579 Other non-current assets 1,423 million in new and renewal property, plant and equipment.
This is mainly related to a large number of projects for the renewal, Total non-current assets 25,292 22,124 improvement and expansion of facilities at various worldwide sites.
Current assets Property is mainly held freehold.
New investment is financed from Inventories 4,064 4,056 Group liquid resources.
At 31st December 2009, GSK had capital Current tax recoverable 58 76 contractual commitments for future expenditure of 416 million Trade and other receivables 6,492 6,265 and operating lease commitments of 337 million.
GSK believes Derivative financial instruments 129 856 that its facilities are adequate for its current needs.
Liquid investments 268 391 The Group observes stringent procedures and uses specialist Cash and cash equivalents 6,545 5,623 skills to manage environmental risks from these activities.
Assets held for sale 14 2 Environmental issues, sometimes dating from operations now 17,570 17,269 Total current assets modified or discontinued, are reported under Responsibility and the environment page 24 and in Note 44 to the financial Total assets 42,862 39,393 statements, Legal proceedings.
Liabilities Goodwill Current liabilities Goodwill has increased during the year from 2,101 million at Short-term borrowings 1,471 956 31st December 2008 to 3,361 million.
The increase primarily Trade and other payables 6,772 6,075 reflects the goodwill arising on the acquisition of Stiefel Derivative financial instruments 168 752 Laboratories, Inc. of 885 million, the Pfizer HIV business of Current tax payable 1,451 780 255 million and certain businesses from UCB S. A. of 87 million.
Short-term provisions 2,256 1,454 Other intangible assets Total current liabilities 12,118 10,017 Other intangible assets include the cost of intangibles acquired from Non-current liabilities third parties and computer software.
The net book value of other Long-term borrowings 14,786 15,231 intangible assets as at 31st December 2009 was 8,183 million Deferred tax liabilities 645 714 2008 5,869 million.
The increase in 2009 reflects additions Pensions and other post-employment benefits 2,981 3,039 of 3,167 million partly offset by currency movements and the Other provisions 985 1,645 amortisation and impairment of existing intangibles.
The largest element Derivative financial instruments 2 of the additions is 1,513 million relating to the acquisition of Stiefel 605 427 Other non-current liabilities Laboratories, Inc. reflecting the brands acquired together with the Stiefel trade name.
In addition, 595 million relates to the fair value of Total non-current liabilities 20,002 21,058 the Pfizer HIV intellectual property acquired following the creation of Total liabilities 32,120 31,075 the ViiV Healthcare business during the year and a further 445 million Net assets 10,742 8,318 arises from the acquisition of certain businesses from UCB S. A.
Equity 1,416 1,415 Share capital Share premium account 1,368 1,326 Retained earnings 6,321 4,622 900 568 Other reserves Shareholders equity 10,005 7,931 Minority interests 737 387 Total equity 10,742 8,318 GSK Annual Report 2009 Business review P06P53 Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 37 Financial position and resources Investments Provisions GSK held investments, including associates and joint ventures, The Group carried deferred tax provisions and other short-term and with a carrying value at 31st December 2009 of 1,349 million non-current provisions of 3,886 million at 31st December 2009 2008 1,030 million.
The market value at 31st December 2009 2008 3,813 million in respect of estimated future liabilities, of was 2,225 million 2008 1,883 million.
The largest of these which 2,020 million related to legal and other disputes.
Provision investments are in two associates: Quest Diagnostics Inc. which has been made for legal and other disputes, indemnified disposal had a book value at 31st December 2009 of 410 million liabilities and the costs of restructuring programmes to the extent 2008 463 million and Aspen Pharmacare Holdings Limited, that at the balance sheet date an actual or constructive obligation acquired this year, which had a book value at 31st December existed and could be reasonably estimated.
The investments include equity stakes in Pensions and other post-employment benefits companies where the Group has research collaborations, which The Group accounts for pension and other post-employment provide access to biotechnology developments of potential interest arrangements in accordance with IAS 19.
The deficits, net of and interests in companies that arise from business divestments.
surpluses before allowing for deferred taxation were 1,745 million Derivative financial instruments: assets 2008 1,697 million on pension arrangements and GSK had both non-current and current derivative financial 1,213 million 2008 1,303 million on unfunded postinstruments held at fair value of 197 million 2008 963 million.
The pension liabilities increased following a The decrease primarily reflects lower currency volatility in Euro, weakening of long term interest rates, including a reduction in the US dollar and Yen market rates.
rate used to discount UK pension liabilities from 6.20% to 5.70% and an increase in the estimated long term inflation rate in the Inventories UK, partly offset by a positive impact of exchange movements and Inventory of 4,064 million has increased by 8 million during higher asset values.
The increase arises from H1N1 vaccine and Synflorix stockNet debt builds following regulatory approval in key markets: the acquisition of Stiefel Laboratories, Inc. : strategic stock building to support 2009 2008 m m growth in Emerging Markets and Japan, offset by a weakening of Cash, cash equivalents and overseas currencies and improvements following implementation of the working capital reduction programme.
liquid investments 6,813 6,014 Borrowings repayable within one year 1,471 956 Trade and other receivables Borrowings repayable after one year 14,786 15,231 Trade and other receivables of 6,492 million have increased from Net debt 9,444 10,173 2008 reflecting the relatively high vaccine sales of H1N1 in the last quarter together with the Stiefel acquisition, partly offset by the Net debt decreased by 729 million primarily from a weakening of impact of a weakening of overseas currencies on the translation of the foreign currencies in which Group debt is denominated.
foreign currency receivables, the sale of long outstanding debt in certain European markets and Taiwan and reductions in overdue Total equity receivables in certain European and Asian markets.
A summary of the movements in equity is set out below.
Derivative financial instruments: liabilities 2009 2008 GSK held current derivative financial instruments held at fair m m value of 168 million 2008 752 million current and 2 million Total equity at beginning of year 8,318 9,910 non-current relating primarily to hedging exchange on translation Total comprehensive income for the year 4,996 4,829 of currency assets on consolidation.
The decrease again reflects Dividends to shareholders 3,003 2,929 lower currency volatility on the Euro, US dollar and Yen.
Ordinary Shares issued 43 62 Trade and other payables Ordinary Shares purchased and cancelled 3,706 Changes in minority shareholdings 338 Trade and other payables amounting to 6,772 million have Put option over minority interest 2 increased from 2008 primarily reflecting working capital Consideration received for shares transferred improvement initiatives to extend supplier terms towards the by ESOP Trusts 13 10 Groups 60 day term objective and the acquisition of Stiefel Laboratories Inc. partly offset by a weakening of year-end Ordinary Shares acquired by ESOP Trusts 57 19 foreign exchange rates.
Share-based incentive plans 171 241 Tax on share-based incentive plans 14 1 Distributions to minority interests 89 79 Total equity at end of year 10,742 8,318 At 31st December 2009, total equity had increased from 8,318 million at 31st December 2008 to 10,742 million.
The increase arises principally from retained profit for the year partly offset by actuarial losses on defined benefit pension plans.
GSK Annual Report 2009 38 Financial position and resources Share purchases Contractual obligations and commitments In 2009, the Employee Share Ownership Plan ESOP Trusts The following table sets out the Groups contractual obligations and acquired 57 million of shares in GSK plc 2008 19 million.
commitments at 31st December 2009 as they fall due for payment.
Shares are held by the Trusts to satisfy future exercises of options Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs and awards under the Group share option and award schemes.
m m m m m A proportion of the shares held by the Trusts are in respect of Loans 16,127 1,431 2,647 2,538 9,511 awards where the rules of the scheme require GSK to satisfy Interest on loans 10,733 757 1,507 1,130 7,339 exercises through market purchases rather than the issue of new Finance lease obligations 130 40 56 19 15 shares.
The shares held by the Trusts are matched to options and Finance lease charges 16 4 8 3 1 awards granted.
Operating lease At 31st December 2009, the ESOP Trusts held 118 million commitments 337 111 122 35 69 2008 129 million GSK shares against the future exercise Intangible assets 12,280 694 1,189 2,022 8,375 of share options and share awards.
The carrying value of Property, plant & equipment 416 300 74 42 1,138 million 2008 1,445 million has been deducted from Investments 86 37 12 37 other reserves.
The market value of these shares was Purchase commitments 82 60 21 1 1,554 million 2008 1,657 million.
Pensions 1,460 365 730 365 Other commitments 52 8 17 22 5 GSK did not repurchase any shares for cancellation in 2009 2008 3,706 million or any shares to be held as Treasury shares Total 41,719 3,807 6,383 6,214 25,315 2008 nil.
In order to ensure that GSK has sufficient flexibility to deliver its strategic priorities the company does not expect to Commitments in respect of loans and future interest payable make any significant repurchases under the existing share buy-back on loans are disclosed before taking into account the effect programme during 2010.
The exact amount and timing of future of derivatives.
The Group has entered into a number of purchases, and the extent to which repurchased shares will be held research collaborations to develop new compounds with other as Treasury shares rather than being cancelled, will be determined pharmaceutical companies.
The terms of these arrangements can by the company and is dependent on market conditions and other include upfront fees, equity investments, loans and commitments factors.
At 31st December 2009, GSK held 474.2 million shares as to fund specified levels of research.
In addition, the Group will Treasury shares 2008 474.2 million shares, at a cost of often agree to make further payments if future milestones are 6,286 million 2008 6,286 million, which has been deducted achieved.
As some of these agreements relate to compounds in from retained earnings.
the early stages of development, milestone payments will continue for a number of years if the compounds move successfully through There have been no purchases since 31st December 2009 under the development process.
Generally the closer the product is to the existing programme.
marketing approval the greater the possibility of success.
The Commitments and contingent liabilities payments shown above within intangible assets represent the Financial commitments are summarised in Note 39 to the financial maximum that would be paid if all milestones are achieved.
Other contingent liabilities and A number of new commitments were made in 2009 under obligations in respect of short and long-term debt are set out in licensing and other agreements, including arrangements with Note 31 to the financial statements, Contingent liabilities and Chroma Therapeutics Limited, Concert Pharmaceuticals, Inc. Idenix Note 32 to the financial statements, Net debt.
Pharmaceuticals, Inc. Prosensa B. V. and Seattle Genetics, Inc.
Amounts provided for pensions and post-retirement benefits are In 2009, GSK reached an agreement with the trustees of the UK set out in Note 28 to the financial statements, Pensions and other pension schemes to make additional contributions over a five year post-employment benefits.
Amounts provided for restructuring period, to eliminate the pension deficit identified at the programmes and legal, environmental and other disputes are set 31st December 2008 actuarial funding valuation.
The table above out in Note 29 to the financial statements, Other provisions.
shows this commitment but excludes the normal ongoing annual funding requirement of approximately 150 million.
For further information on pension obligations, see Note 28 to the financial statements, Pensions and other post-employment benefits.
GSK Annual Report 2009 Business review P06P53 Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 39 Financial position and resources The net cash outflow from investing activities was 4,013 million, Contingent liabilities an increase of 2,864 million which primarily reflected a significant The following table sets out contingent liabilities, comprising increase in the cost of business purchases during 2009, including discounted bills, performance guarantees, letters of credit and other Stiefel Laboratories, Inc. for 1,993 million net of cash acquired of items arising in the normal course of business, and when they are 74 million, certain businesses from UCB S. A. for 472 million net expected to expire.
of cash acquired of 5 million, and AZ Tika for 146 million.
In 2008, Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs the comparable acquisitions comprised Sirtris Pharmaceuticals for m m m m m 324 million net of cash acquired of 52 million, and the Egyptian Guarantees 110 72 28 10 business of BMS for 130 million net of deferred consideration of Other contingent liabilities 40 5 12 2 21 10 million.
In addition sales of liquid investments realised cash of 905 million in 2008.
Total 150 77 40 2 31 Free cash flow In the normal course of business, GSK has provided various m indemnification guarantees in respect of business disposals in which legal and other disputes have subsequently arisen.
A 6,000 provision is made where an outflow of resources is considered 5,000 probable and a reasonable estimate can be made of the likely 5,254 outcome of the dispute and this is included in Note 29 to the 4,679 4,000 financial statements, Other provisions.
3,000 It is the Groups policy to provide for the settlement costs of asserted claims and environmental disputes when an outflow of 2,000 resources is considered probable and a reasonable estimate may 1,000 be made.
Prior to this point no liability is recorded.
Legal and environmental costs are discussed in Risk factors on pages 43 0 to 47 and Note 44 to the financial statements, Legal 2009 2008 proceedings.
GSK continues to believe that it has made adequate provision for the liabilities likely to arise from open taxation Free cash flow is the amount of cash generated by the business assessments.
The ultimate liability for such matters may vary after meeting its obligations for interest, tax and dividends paid significantly from amounts provided and is dependent upon the to minority interests, and after capital expenditure on non-current outcome of litigation proceedings and negotiations with the tangible and intangible assets.
For 2009 free cash flow was relevant tax authorities.
This is discussed further in Note 14 to the 5,254 million, an increase of 12% over 2008.
This principally financial statements, Taxation.
reflected the higher operating profit before non-cash charges primarily from the major restructuring programmes and lower Cash flow expenditure on intangible assets.
This was partly offset by higher A summary of the consolidated cash flow is set out below.
levels of net interest paid as a result of the debt issuance during the year of 1.6 billion under the EMTN programme and reduced 2009 2008 m m interest income on deposits.
Net cash inflow from operating activities 7,841 7,205 Free cash flow is used by GSKs management for planning and Net cash outflow from investing activities 4,013 1,149 reporting purposes and in discussions with and presentations to Net cash outflow from financing activities 2,774 4,908 investment analysts and rating agencies.
GSKs free cash flow measure is not defined in IFRS.
This measure may not be directly Increase in cash and bank overdrafts 1,054 1,148 comparable with similarly described measures used by other Exchange adjustments 158 1,103 companies.
A reconciliation of net cash inflow from operating Cash and bank overdrafts at beginning of year 5,472 3,221 activities, which is the closest equivalent IFRS measure, to free cash flow is shown below.
Cash and bank overdrafts at end of year 6,368 5,472 Reconciliation of free cash flow Cash and bank overdrafts at end of year comprise: 2009 2008 m m Cash and cash equivalents 6,545 5,623 Net cash inflow from operating activities 7,841 7,205 Overdrafts 177 151 Purchase of property, plant and equipment 1,418 1,437 6,368 5,472 Purchase of non-current intangible assets 455 632 Disposal of property, plant and equipment 48 20 The net cash inflow from operating activities after taxation paid was Interest paid 780 730 7,841 million, an increase of 636 million over 2008 reflecting higher Interest received 90 320 profit before tax, excluding the impact of the significant increase in Dividends received from joint ventures and non-cash charges made in the year, primarily from the major associated undertaking 17 12 restructuring programmes.
Dividends paid to minority interests 89 79 Free cash flow 5,254 4,679 GSK Annual Report 2009 40 Financial position and resources Movements in net debt Payment policies Group companies are responsible for monitoring and managing 2009 2008 their working capital.
The terms of sales collections and supplier m m payments reflect local commercial practice.
Net debt at beginning of year 10,173 6,039 In the UK, the company and each of its UK subsidiaries have Increase in cash and bank overdrafts 1,054 1,148 policies to ensure that suppliers are paid on time.
In particular, Cash inflow from liquid investments 87 905 the UK companies seek: Net increase in long-term loans 1,358 5,523 Net repayment of short-term loans 102 3,059 t o settle terms of payment with suppliers when agreeing the Debt of subsidiary undertakings acquired 9 terms of the transaction Exchange movements 1,041 1,918 t o ensure that suppliers are made aware of the agreed terms Other movements 14 5 of payment Net debt at end of year 9,444 10,173 to abide by the terms of payment.
The policy permits arrangements for accelerated payment to Investment appraisal small suppliers.
GSK has a formal process for assessing potential investment proposals in order to ensure decisions are aligned with the Payment performance Groups overall strategy.
This process includes an analysis of At 31st December 2009, the average number of days payable the impact of the project on earnings, its return on invested outstanding represented by trade payables of the parent company capital and an assessment of the return based on discounted was nil 2008 nil and in respect of the company and its UK cash flows.
The discount rate used to perform financial analysis subsidiaries in aggregate was 44 days 2008 20 days.
is decided internally, to allow determination of the extent to Treasury policies which investments cover the Groups cost of capital.
For specific investments the discount rate may be adjusted to take into GSK reports in Sterling and pays dividends out of Sterling profits.
account country or other risk weightings.
The role of Corporate Treasury is to manage and monitor our external and internal funding requirements and financial risks in Capital expenditure and financial investment support of our strategic objectives.
Treasury activities are governed Cash payments for tangible and intangible fixed assets amounted by policies and procedures approved by the Board of Directors, to 1,873 million 2008 2,069 million: 2007 2,143 million.
Disposals realised 404 million 2008 191 million: 2007 44 million.
Cash payments to acquire equity investments A Treasury Management Group TMG chaired by our Chief of 154 million 2008 87 million: 2007 186 million were Financial Officer, meets on a monthly basis to review treasury made in the year and sales of equity investments realised activities.
Its members receive management information relating 59 million 2008 42 million: 2007 45 million.
Capital management Future cash flow The Group expects that future operating cash flow will be GSK operates on a global basis, primarily through subsidiary sufficient to fund its operating and debt service costs, to satisfy companies established in the markets in which we trade.
With normal levels of capital expenditure, to meet obligations under significant levels of patent or trademark protection, our products existing licensing agreements, to meet the expenditure arising from compete largely on product efficacy or differentiation rather than the major restructuring programmes the precise timing of which on price.
Selling margins are sufficient to cover normal operating is uncertain outlined in Note 7 to the financial statements, Major costs and our operating subsidiaries are generally cash generative.
restructuring programmes and to meet other routine outflows Operating cash flow is used to fund investment in research and including tax and dividends, subject to the Risk factors discussed development of new products.
It is also used to make the routine on pages 43 to 47.
GSK may from time to time have additional outflows of capital expenditure, tax, dividends, repayment of demands for finance, such as for acquisitions.
It has access to other maturing debt and, to the extent determined by the Board, sources of liquidity from short and long-term capital markets and share repurchases.
banks and other financial institutions, in addition to the cash flow from operations, for such needs.
Our policy is to borrow centrally using a variety of capital market issues and borrowing facilities to meet anticipated funding requirements.
These borrowings, together with cash generated from operations, are on-lent, contributed as equity to certain subsidiaries or used to pay dividends and make acquisitions.
GSK did not make any share repurchases in 2009.
GSK Annual Report 2009 Business review P06P53 Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 41 Financial position and resources Liquidity At 31st December 2009, we had centrally available cash reserves of 4.9 billion and committed undrawn bank facilities of $3.9 billion.
As at 31st December 2009, our cash and liquid investments were As at that date we had short-term debt and bank overdrafts and held as follows: loans repayable within one year of 1.5 billion.
2009 2008 m m We manage our net borrowing requirements through a portfolio of long-term borrowings, including bonds, together with shortBank balances and deposits 5,206 3,778 term finance under a $10 billion commercial paper programme.
US Treasury and Treasury repo The commercial paper programme is backed by $3.9 billion of only money market funds 1,305 1,852 committed facilities.
The facilities were last renewed in October Corporate debt instruments 10 75 2009.
We consider this level of committed facilities to be adequate Government securities 292 309 given our current cash holdings.
For further information on these 6,813 6,014 facilities, see Note 32 to the financial statements, Net debt.
We also benefit from strong positive cash flow from operating units.
4.9 billion of this amount is managed centrally and available We have a European Medium Term Note programme of within three months.
We had net debt at 31st December 2009 of 15 billion.
At 31st December 2009, we had 8.5 billion of 9.4 billion.
The table below summarises cash and gross debt after notes in issue under this programme.
We also have a US shelf the effects of hedging.
At 31st December 2009, we had 2009 2008 $11 billion 6.9 billion of notes in issue under this programme.
m m The TMG monitors the cash flow forecast on a monthly basis.
Cash and liquid investments 6,813 6,014 The long-term borrowings mature at dates between 2012 and Gross debt fixed 13,706 13,814 2042.
Our long-term debt ratings have remained stable since floating 2,550 2,373 February 2008.
Currently we are rated A stable outlook by non-interest bearing 1 Standard and Poors and A1 stable outlook by Moodys.
Our Net debt 9,444 10,173 short-term debt ratings are A-1 and P-1 with Standard and Poors and Moodys respectively.
The maturity profile of gross debt is shown in the table below: Maturity profile of gross debt m equivalent 3,000 2,500 2,000 1,500 1,000 500 2010 2011 2012 2013 2014 2015 2016 2017 2018 2025 2033 2034 2038 2039 2042 GBP bonds EUR bonds USD bonds Commercial paper Other borrowings Leases GSK Annual Report 2009 42 Financial position and resources We use an interest rate swap to re-denominate one of our external Treasury operations borrowings into the interest rate coupon required by GSK.
The The objective of treasury activity is to manage the post-tax net duration of this swap matches the duration of the principal cost or income of financial operations to the benefit of earnings.
Interest rate derivative instruments are accounted for Corporate Treasury does not operate as a profit centre.
We use as fair value or cash flow hedges of the relevant assets or liabilities.
a variety of financial instruments to finance our operations and derivative financial instruments to manage market risks from Counterparty risk management these operations.
These derivatives, principally comprising forward Our policy on counterparty risk management is to work with foreign currency contracts, interest rate and currency swaps, a select group of relationship banks.
Global counterparty are used to swap borrowings and liquid assets into our required limits are assigned to each of GSKs banking and investment currencies and to manage exposure to funding risks from changes counterparties based on long-term credit ratings from Moodys in foreign exchange and interest rates.
Corporate Treasurys usage of these limits is monitored daily by a Corporate Compliance Officer CCO We do not hold or issue derivatives for speculative purposes.
Our who operates independently of Corporate Treasury.
Any breach treasury policies specifically prohibit such activity.
All transactions of these limits is reported to the CFO immediately.
The CCO also in financial instruments are undertaken to manage the risks arising monitors the credit rating of these counterparties and, when from underlying business activities, not for speculation.
changes in ratings occur, notifies Corporate Treasury so that Foreign exchange management changes can be made to investment levels or authority limits as Foreign currency transaction exposures arising on internal and appropriate.
A full counterparty analysis is presented to the TMG external trade flows are not hedged.
The exposure of overseas annually for approval.
operating subsidiaries to transaction risk is minimised by matching Financial assets and liabilities local currency income with local currency costs.
An analysis of net debt is given in Note 32 to the financial For this purpose, our internal trading transactions are matched statements, Net debt.
An analysis of financial assets and liabilities centrally and we manage intercompany payment terms to reduce at carrying value and fair value is given in Note 41 to the financial foreign currency risk.
Exceptional foreign currency cash flows are statements, Financial instruments and related disclosures.
hedged selectively under the management of Corporate Treasury.
We continue to benefit from strong positive cash flow from We manage the short-term cash surpluses or borrowing operating activities.
Our net debt has decreased in the year to requirements of subsidiary companies centrally using forward 31st December 2009, despite GSKs acquisition activities in the contracts to hedge future repayments back into the period which totalled approximately 2.8 billion.
information on these activities, see Note 38 to the financial We seek to denominate borrowings in the currencies of our statements, Acquisitions and Disposals.
principal assets and cash flows.
These are primarily denominated The financial assets and liabilities at 31st December 2009 are in US dollars, Euros and Sterling.
Certain borrowings are swapped representative of our treasury policies and strategies applied into other currencies as required.
In 2009 GSK raised approximately 1.4 billion Borrowings denominated in, or swapped into, foreign currencies 2008 6.3 billion in the Capital Markets.
We did not make that match investments in our overseas assets may be treated as any share repurchases in 2009. a hedge against the relevant assets.
Forward contracts are also used in major currencies to reduce our exposure to our investment in overseas Group assets see Net Investment Hedges section of Note 41 for further details.
The TMG reviews the ratio of borrowings to assets for major currencies.
Interest rate risk management The policy on interest rate risk management limits the amount of floating interest payments to a perscribed percentage of trading profit.
GSK Annual Report 2009 Business review P06P53
